MedKoo Cat#: 564707 | Name: C-178
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

C-178 is a covalent inhibitor of STING, blocking palmitoylation-induced clustering of STING.

Chemical Structure

C-178
C-178
CAS#329198-87-0

Theoretical Analysis

MedKoo Cat#: 564707

Name: C-178

CAS#: 329198-87-0

Chemical Formula: C17H10N2O5

Exact Mass: 322.0590

Molecular Weight: 322.28

Elemental Analysis: C, 63.36; H, 3.13; N, 8.69; O, 24.82

Price and Availability

Size Price Availability Quantity
10mg USD 90.00 Ready to ship
25mg USD 150.00 Ready to ship
50mg USD 250.00 Ready to ship
100mg USD 450.00 Ready to ship
200mg USD 750.00 Ready to ship
500mg USD 1,650.00 Ready to Ship
1g USD 2,950.00 Ready to Ship
2g USD 5,250.00 Ready to Ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
C178; C 178; C-178, STING inhibitor C-178
IUPAC/Chemical Name
N-(Dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide
InChi Key
URUVDCCYSJEGQQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H10N2O5/c20-17(14-7-8-16(24-14)19(21)22)18-10-5-6-12-11-3-1-2-4-13(11)23-15(12)9-10/h1-9H,(H,18,20)
SMILES Code
O=C(C1=CC=C([N+]([O-])=O)O1)NC2=CC=C3C(OC4=CC=CC=C34)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
C-178 is a covalent STING inhibitor.
In vitro activity:
To be determined
In vivo activity:
To be determined
Solvent mg/mL mM
Solubility
DMSO 2.0 6.21
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 322.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
To be determined
In vitro protocol:
To be determined
In vivo protocol:
To be determined
1: Xu J, Zheng Y, Cheng L, Sun H, Yu X, Gu F, Song E. GPR143 mutations in an X-linked infantile nystagmus syndrome cohort in Southeast China. Mol Vis. 2023 Nov 1;29:234-244. PMID: 38222445; PMCID: PMC10784212. 2: El Hawary R, Meshaal S, Lotfy S, Abd Elaziz D, Alkady R, Eldash A, Erfan A, Chohayeb E, Saad M, Darwish R, Boutros J, Galal N, Elmarsafy A. Cernunnos deficiency: Further delineation in 5 Egyptian patients. Eur J Med Genet. 2023 Oct;66(10):104840. doi: 10.1016/j.ejmg.2023.104840. Epub 2023 Sep 11. PMID: 37703920. 3: He J, Sun M, Li E, Hou Y, Shepard MJ, Chen D, Pacak K, Wang C, Guo L, Zhuang Z, Liu Y. Recurrent somatic mutations of PRKAR1A in isolated cardiac myxoma. Oncotarget. 2017 Oct 19;8(61):103968-103974. doi: 10.18632/oncotarget.21916. PMID: 29262613; PMCID: PMC5732779. 4: Song X, Wang M, Liu S, Liu H, Jiang A, Zou Y, Deng Y, Qin Q, Song Y, Zheng Y. A sequential scheme including PTT and 2'3'-cGAMP/CQ-LP reveals the antitumor immune function of PTT through the type I interferon pathway. Pharmacol Res. 2023 Oct;196:106939. doi: 10.1016/j.phrs.2023.106939. Epub 2023 Sep 25. PMID: 37758101. 5: Van Poucke M, Stee K, Sonck L, Stock E, Bosseler L, Van Dorpe J, Van Nieuwerburgh F, Deforce D, Peelman LJ, Van Ham L, Bhatti SFM, Broeckx BJG. Truncating SLC12A6 variants cause different clinical phenotypes in humans and dogs. Eur J Hum Genet. 2019 Oct;27(10):1561-1568. doi: 10.1038/s41431-019-0432-3. Epub 2019 Jun 3. PMID: 31160700; PMCID: PMC6777613. 6: Kim S, Kim DH, Jang JH, Jung CW, Jang MA, Ki CS, Kim JW, Kim SH, Kim HJ. Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype. Ann Lab Med. 2012 Mar;32(2):153-7. doi: 10.3343/alm.2012.32.2.153. Epub 2012 Feb 23. PMID: 22389883; PMCID: PMC3289781. 7: Carboni N, Porcu M, Mura M, Cocco E, Marrosu G, Maioli MA, Solla E, Tranquilli S, Orrù P, Marrosu MG. Evolution of the phenotype in a family with an LMNA gene mutation presenting with isolated cardiac involvement. Muscle Nerve. 2010 Jan;41(1):85-91. doi: 10.1002/mus.21443. PMID: 19768759. 8: Moatter T, Kausar T, Aban M, Ghani S, Pal JA. Prenatal screening for β-thalassemia major reveals new and rare mutations in the Pakistani population. Int J Hematol. 2012 Apr;95(4):394-8. doi: 10.1007/s12185-012-1036-7. Epub 2012 Mar 4. PMID: 22392582. 9: Watanabe-Okochi N, Tsuneyama H, Isa K, Sasaki K, Suzuki Y, Yabe R, Tsuno NH, Nakajima K, Ogasawara K, Uchikawa M. Novel hybrid genes and a splice site mutation encoding the Sta antigen among Japanese blood donors. Vox Sang. 2020 Nov;115(8):756-766. doi: 10.1111/vox.12921. Epub 2020 May 11. PMID: 32394466. 10: Misumi S, Takamune N, Ido Y, Hayashi S, Endo M, Mukai R, Tachibana K, Umeda M, Shoji S. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4. Biochem Biophys Res Commun. 2001 Aug 3;285(5):1309-16. doi: 10.1006/bbrc.2001.5267. PMID: 11478800.